USE OF HYPOMETHYLATING AGENTS IN RELAPSED/REFRACTORY PEDIATRIC ACUTE MYELOID LEUKEMIA

被引：0
|
作者：
Sabnis, Himalee [1 ]
Raikar, Sunil [1 ]
Bennett, Anna [1 ]
MacDonald, Kelly [1 ]
Watkins, Benjamin [1 ]
Woods, William [1 ]
Keller, Frank [1 ]
机构：
[1] Childrens Healthcare Atlanta, Atlanta, GA USA
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
81
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [41] Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
    Ron Ram
    Odelia Amit
    Tsila Zuckerman
    Ronit Gurion
    Pia Raanani
    Yael Bar-On
    Irit Avivi
    Ofir Wolach
    Annals of Hematology, 2019, 98 : 1927 - 1932
  • [42] Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
    Deveaux, Michelle
    Stahl, Maximilian
    Montesinos, Pau
    Itzykson, Raphael
    Ritchie, Ellen K.
    Sekeres, Mikkael A.
    Barnard, John
    Podoltsev, Nikolai A.
    Brunner, Andrew M.
    Komrokji, Rami S.
    Bhatt, Vijaya R.
    Al-Kali, Aref
    Cluzeau, Thomas
    Santini, Valeria
    Roboz, Gail J.
    Fenaux, Pierre
    Litzow, Mark R.
    Fathi, Amir T.
    Perreault, Sera
    Kim, Tae Kon
    Prebet, Thomas
    Vey, Norbert
    Verma, Vivek
    Germing, Ulrich
    Bergua, Juan
    Serrano, Josefina
    Gore, Steven D.
    Zeidan, Amer M.
    BLOOD, 2017, 130
  • [43] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    BLOOD, 2012, 120 (21)
  • [44] Venetoclax in Combination with Hypomethylating Agents or Low-Dose Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia: A Retrospective Single-Centre Experience
    Piccini, Matteo
    Pilerci, Sofia
    Scappini, Barbara
    Mannelli, Francesco
    Ciolli, Gaia
    Pasquini, Andrea
    Fasano, Laura
    Quinti, Elisa
    Guglielmelli, Paola
    Mannarelli, Carmela
    Pancani, Fabiana
    Zizza, Michela
    Signori, Leonardo
    Vannucchi, Alessandro M.
    Gianfaldoni, Giacomo
    BLOOD, 2022, 140 : 9008 - 9009
  • [45] Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
    Maiti, Abhishek
    Rausch, Caitlin R.
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Daver, Naval G.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Naqvi, Kiran
    Ohanian, Maro
    Short, Nicholas J.
    Alvarado, Yesid
    Kadia, Tapan M.
    Takahashi, Koichi
    Yilmaz, Musa
    Jain, Nitin
    Kornblau, Steven
    Montalban-Bravo, Guillermo
    Sasaki, Koji
    Andreeff, Michael
    Bose, Prithviraj
    Ferrajoli, Alessandra
    Issa, Ghayas C.
    Jabbour, Elias J.
    Masarova, Lucia
    Thompson, Philip A.
    Wang, Sa
    Konoplev, Sergej
    Pierce, Sherry A.
    Ning, Jing
    Qiao, Wei
    Welch, John S.
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    Konopleva, Marina Y.
    HAEMATOLOGICA, 2021, 106 (03) : 894 - 898
  • [46] The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
    Jiang, Xuejie
    Wang, Zhixiang
    Ding, Bingjie
    Yin, Changxin
    Zhong, Qingxiu
    Carter, Bing Z.
    Yu, Guopan
    Jiang, Ling
    Ye, Jieyu
    Dai, Min
    Zhang, Yu
    Liang, Shuang
    Zhao, Qingxia
    Liu, Qifa
    Meng, Fanyi
    ONCOTARGET, 2015, 6 (32) : 33612 - 33622
  • [47] The Hypomethylating Agent Decitabine Prior to Chemotherapy Improves the Therapy Efficacy in Refractory/Relapsed Acute Myeloid Leukemia Patients
    Jiang, Xuejie
    Wang, Zhixiang
    Yin, Changxin
    Yu, Guopan
    Ye, Jieyu
    Zhang, Yu
    Fan, Zhiping
    Xu, Dan
    Liu, Xiaoli
    Feng, Ru
    Xu, Bing
    Sun, Jing
    Liu, Qifa
    Carter, Bing Z.
    Meng, Fanyi
    BLOOD, 2015, 126 (23)
  • [48] Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
    Steinauer, Nickolas
    McCullough, Kristen
    Al-Kali, Aref
    Alkhateeb, Hassan B.
    Begna, Kebede H.
    Mangaonkar, Abhishek A.
    Saliba, Antoine N.
    Torghabeh, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun
    Patnaik, Mrinal M.
    Pardanani, Animesh
    Badar, Talha
    Murthy, Hemant
    Foran, James
    Yi, Cecilia Arana
    Tefferi, Ayalew
    Gangat, Naseema
    HAEMATOLOGICA, 2024, 109 (08) : 2706 - 2710
  • [49] NATIONAL EXPERIENCE WITH THE USE OF VENETOCLAX IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
    Labrador, J.
    Saiz-Rodriguez, M.
    De Miguel, D.
    Vidriales, M. B.
    Perez-Encinas, M.
    Sanchez-Sanchez, M. J.
    Cuello, R.
    Roldan-Perez, A.
    Vives, S.
    Benzo-Callejo, G.
    Colorado, M.
    Garcia-Fortes, M.
    Sayas, M. J.
    Olivier, C.
    Recio, I
    Seri-Merino, C.
    Tormo, M.
    Vall-llovera, F.
    Foncillas, M. A.
    Montesinos, P.
    HAEMATOLOGICA, 2020, 105 : 56 - 56
  • [50] Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA
    Emma H. McCafferty
    Katherine A. Lyseng-Williamson
    Drugs & Therapy Perspectives, 2019, 35 : 160 - 166
12345